Omic-signature of bronchopulmonary dysplasia associated pulmonary hypertension in <1500g-birth-weight-infants with hemodynamically significant intracardiac shunt.


Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
13 Sep 2024
Historique:
received: 19 02 2024
accepted: 21 08 2024
revised: 01 08 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

PDA and ASD are common intracardiac shunts noted in prematurely born infants. While there is evidence of persistent PDA and ASD associated with a higher risk for developing bronchopulmonary dysplasia (ICS-BPD) and pulmonary hypertension (ICS-BPD-PH), the underlying pathogenesis is poorly understood and hence challenging to identify at-risk infants. Our study goal was to evaluate transcriptomic expression and associated pathways in tracheal aspirates (TAs) of low-birth-weight infants with hemodynamically significant cardiac shunt (ICS) that develop bronchopulmonary dysplasia (ICS-BPD) and pulmonary hypertension (ICS-BPD-PH). TAs were collected from preterm infants with ICS and a diagnosis of BPD or BPD-PH from a single center. 36 TA samples including 19 ICS-BPD and 17 ICS-BPD-PH were analyzed. MiRNA expression was determined via PCR arrays, and mRNA expression via RNA seq. Data were analyzed using limma. 11 miRNAs and 10 mRNAs were differentially expressed (adjusted p < 0.05) in ICS-BPD-PH group when compared to ICS-BPD. Ingenuity Pathway Analysis identified associations with cellular growth, proliferation, death, and cell function pathways. TAs from preterm infants show differentially expressed miRNAs and mRNAs in ICS-BPD-PH when compared to ICS-BPD, an in-silico model identified target molecules that could be playing a role in BPD-PH pathogenesis in low-birth-weight infants with ICS. Pulmonary hypertension associated with severe BPD (BPD-PH) is a distinct disease in preterm infants with severe BPD and the role of intracardiac shunt (ICS) in its development is controversial and often challenging for clinical management. Our pilot study, researching specific endotyping of infants with pulmonary hypertension associated with BPD using multiomics approach has identified molecular markers and potential underlying pathways associated with this condition. These markers could aid in stratifying high risk infants with ICS that are at risk for developing BPD-PH and aid clinical management.

Sections du résumé

BACKGROUND BACKGROUND
PDA and ASD are common intracardiac shunts noted in prematurely born infants. While there is evidence of persistent PDA and ASD associated with a higher risk for developing bronchopulmonary dysplasia (ICS-BPD) and pulmonary hypertension (ICS-BPD-PH), the underlying pathogenesis is poorly understood and hence challenging to identify at-risk infants. Our study goal was to evaluate transcriptomic expression and associated pathways in tracheal aspirates (TAs) of low-birth-weight infants with hemodynamically significant cardiac shunt (ICS) that develop bronchopulmonary dysplasia (ICS-BPD) and pulmonary hypertension (ICS-BPD-PH).
METHODS METHODS
TAs were collected from preterm infants with ICS and a diagnosis of BPD or BPD-PH from a single center. 36 TA samples including 19 ICS-BPD and 17 ICS-BPD-PH were analyzed. MiRNA expression was determined via PCR arrays, and mRNA expression via RNA seq. Data were analyzed using limma.
RESULTS RESULTS
11 miRNAs and 10 mRNAs were differentially expressed (adjusted p < 0.05) in ICS-BPD-PH group when compared to ICS-BPD. Ingenuity Pathway Analysis identified associations with cellular growth, proliferation, death, and cell function pathways.
CONCLUSION CONCLUSIONS
TAs from preterm infants show differentially expressed miRNAs and mRNAs in ICS-BPD-PH when compared to ICS-BPD, an in-silico model identified target molecules that could be playing a role in BPD-PH pathogenesis in low-birth-weight infants with ICS.
IMPACT CONCLUSIONS
Pulmonary hypertension associated with severe BPD (BPD-PH) is a distinct disease in preterm infants with severe BPD and the role of intracardiac shunt (ICS) in its development is controversial and often challenging for clinical management. Our pilot study, researching specific endotyping of infants with pulmonary hypertension associated with BPD using multiomics approach has identified molecular markers and potential underlying pathways associated with this condition. These markers could aid in stratifying high risk infants with ICS that are at risk for developing BPD-PH and aid clinical management.

Identifiants

pubmed: 39271902
doi: 10.1038/s41390-024-03541-5
pii: 10.1038/s41390-024-03541-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Références

Bouma, B. J. & Mulder, B. J. Changing landscape of congenital heart disease. Circ. Res. 120, 908–922 (2017).
doi: 10.1161/CIRCRESAHA.116.309302 pubmed: 28302739
van der Bom, T. et al. The changing epidemiology of congenital heart disease. Nat. Rev. Cardiol. 8, 50–60 (2011).
doi: 10.1038/nrcardio.2010.166 pubmed: 21045784
Parkerson, S., Philip, R., Talati, A. & Sathanandam, S. Management of patent ductus arteriosus in premature infants in 2020. Front. Pediatr. 8, 590578 (2020).
doi: 10.3389/fped.2020.590578 pubmed: 33643964
Rolland, A., Shankar-Aguilera, S., Diomande, D., Zupan-Simunek, V. & Boileau, P. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch. Dis. Child Fetal Neonatal Ed. 100, F55–F58 (2015).
doi: 10.1136/archdischild-2014-306339 pubmed: 25169243
Ruoss, J. L., Bazacliu, C., Giesinger, R. E. & McNamara, P. J. Patent ductus arteriosus and cerebral, cardiac, and gut hemodynamics in premature neonates. Semin. Fetal Neonatal. Med. 25, 101120 (2020).
doi: 10.1016/j.siny.2020.101120 pubmed: 32513596
Mitra, S. & McNamara, P. J. Patent ductus arteriosus-time for a definitive trial. Clin. Perinatol. 47, 617–639 (2020).
doi: 10.1016/j.clp.2020.05.007 pubmed: 32713454
Jain, A. & McNamara, P. J. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin. Fetal. Neonatal. Med. 20, 262–271 (2015).
doi: 10.1016/j.siny.2015.03.001 pubmed: 25843770
Hosono, S. et al. Developmental outcomes in persistent pulmonary hypertension treated with nitric oxide therapy. Pediatr. Int. 51, 79–83 (2009).
doi: 10.1111/j.1442-200X.2008.02664.x pubmed: 19371283
Lam, C. F., Peterson, T. E., Croatt, A. J., Nath, K. A. & Katusic, Z. S. Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 289, H2334–H2341 (2005).
doi: 10.1152/ajpheart.00375.2005 pubmed: 15964923
Olgunturk, R. Pediatric pulmonary hypertension and pulmonary arterial hypertension secondary to congenital heart diseases. Anadolu Kardiyol. Derg. 10, 50–56 (2010).
doi: 10.5152/akd.2010.119 pubmed: 20819767
Coalson, J. J. Pathology of bronchopulmonary dysplasia. Semin. Perinatol. 30, 179–184 (2006).
doi: 10.1053/j.semperi.2006.05.004 pubmed: 16860157
Menon, R. T., Shrestha, A. K., Barrios, R. & Shivanna, B. Hyperoxia disrupts extracellular signal-regulated kinases 1/2-induced angiogenesis in the developing lungs. Int. J. Mol. Sci. 19, 1525 (2018).
doi: 10.3390/ijms19051525 pubmed: 29783779 pmcid: 5983575
Oji-Mmuo, C. N. et al. Tracheal aspirate transcriptomic and mirna signatures of extreme premature birth with bronchopulmonary dysplasia. J. Perinatol. 41, 551–561 (2021).
doi: 10.1038/s41372-020-00868-9 pubmed: 33177681
Rivera, L., Siddaiah, R., Oji-Mmuo, C., Silveyra, G. R. & Silveyra, P. Biomarkers for bronchopulmonary dysplasia in the preterm infant. Front Pediatr. 4, 33 (2016).
doi: 10.3389/fped.2016.00033 pubmed: 27065351 pmcid: 4814627
Siddaiah, R. et al. Early salivary mirna expression in extreme low gestational age newborns. Life (Basel) 12, 506 (2022).
pubmed: 35454997 pmcid: 9029747
Cai, B., Pan, Z. & Lu, Y. The roles of micrornas in heart diseases: a novel important regulator. Curr. Med. Chem. 17, 407–411 (2010).
doi: 10.2174/092986710790226129 pubmed: 20015039
van Rooij, E. & Olson, E. N. Micrornas: powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Invest. 117, 2369–2376 (2007).
doi: 10.1172/JCI33099 pubmed: 17786230 pmcid: 1952642
Nagy, O., Barath, S. & Ujfalusi, A. The role of micrornas in congenital heart disease. EJIFCC 30, 165–178 (2019).
pubmed: 31263391 pmcid: 6599193
Smith, T., Rajakaruna, C., Caputo, M. & Emanueli, C. Micrornas in congenital heart disease. Ann. Transl. Med. 3, 333 (2015).
pubmed: 26734643 pmcid: 4690991
Terrin, G. et al. Echocardiography-guided management of preterms with patent ductus arteriosus influences the outcome: a cohort study. Front Pediatr. 8, 582735 (2020).
doi: 10.3389/fped.2020.582735 pubmed: 33409261 pmcid: 7779760
Singh, Y., Fraisse, A., Erdeve, O. & Atasay, B. Echocardiographic diagnosis and hemodynamic evaluation of patent ductus arteriosus in extremely low gestational age newborn (elgan) infants. Front Pediatr. 8, 573627 (2020).
doi: 10.3389/fped.2020.573627 pubmed: 33330274 pmcid: 7717963
Torres, A. J. Hemodynamic assessment of atrial septal defects. J. Thorac. Dis. 10, S2882–S2889 (2018).
doi: 10.21037/jtd.2018.02.17 pubmed: 30305948 pmcid: 6174148
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616 pubmed: 19910308
Karczewski, K. J. & Snyder, M. P. Integrative omics for health and disease. Nat. Rev. Genet 19, 299–310 (2018).
doi: 10.1038/nrg.2018.4 pubmed: 29479082 pmcid: 5990367
Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293–1307 (2012).
doi: 10.1016/j.cell.2012.02.009 pubmed: 22424236 pmcid: 3341616
Gentle, S. J., Travers, C. P., Clark, M., Carlo, W. A. & Ambalavanan, N. Patent ductus arteriosus and development of bronchopulmonary dysplasia-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med 207, 921–928 (2023).
doi: 10.1164/rccm.202203-0570OC pubmed: 36378949
Philip, R. et al. Effect of patent ductus arteriosus on pulmonary vascular disease. Congenit. Heart Dis. 14, 37–41 (2019).
doi: 10.1111/chd.12702 pubmed: 30811787
Sathanandam, S. et al. Practice variation in the management of patent ductus arteriosus in extremely low birth weight infants in the United States: survey results among cardiologists and neonatologists. Congenit. Heart Dis. 14, 6–14 (2019).
doi: 10.1111/chd.12729 pubmed: 30811803
Choi, E. K. et al. The impact of atrial left-to-right shunt on pulmonary hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Pediatr. Neonatol. 56, 317–323 (2015).
doi: 10.1016/j.pedneo.2014.12.006 pubmed: 26328892
Hundscheid, T. et al. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (Beneductus Trial). BMC Pediatr. 18, 262 (2018).
doi: 10.1186/s12887-018-1215-7 pubmed: 30077184 pmcid: 6090763
Muehlbacher, T., Bassler, D. & Bryant, M. B. Evidence for the management of bronchopulmonary dysplasia in very preterm infants. Child. (Basel) 8, 298 (2021).
Nawaytou, H. et al. Clinical utility of echocardiography in former preterm infants with bronchopulmonary dysplasia. J. Am. Soc. Echocardiogr. 33, 378–388 e371 (2020).
doi: 10.1016/j.echo.2019.10.012 pubmed: 31948712
Kuppahally, S. S. et al. Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation? Am. J. Cardiol. 106, 1657–1662 (2010).
doi: 10.1016/j.amjcard.2010.07.022 pubmed: 21094370
Patel, M. D. et al. Echocardiographic assessment of right ventricular afterload in preterm infants: maturational patterns of pulmonary artery acceleration time over the first year of age and implications for pulmonary hypertension. J. Am. Soc. Echocardiogr. 32, 884–894 e884 (2019).
doi: 10.1016/j.echo.2019.03.015 pubmed: 31272593 pmcid: 6613806

Auteurs

Lucy Emery (L)

Penn State Health College of Medicine, Hershey, PA, USA.

Alexa Hughes (A)

Penn State Health College of Medicine, Hershey, PA, USA.

Christiana Oji-Mmuo (C)

Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA, USA.

Patricia Silveyra (P)

Department of Environmental and Occupational Health, School of Public Health, Indiana University, Bloomington, IN, USA.
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Vincent P R Aluquin (VPR)

Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA, USA.

Ann Donnelly (A)

Department of Respiratory Therapy, Penn State Health Children's Hospital, Hershey, PA, USA.

Roopa Siddaiah (R)

Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA, USA. rsiddaiah@pennstatehealth.psu.edu.

Classifications MeSH